Formulation and Gel Architecture

An HA filler is a manufactured gel system, not a concentration printed on a syringe. Concentration, molecular characteristics, crosslinking, network processing, soluble HA, buffer, lidocaine, and final presentation can interact. No single field establishes how two products compare clinically.

Formulation at a glance

Field	Direct question	Interpretation boundary
HA source	What organism or production route does the exact source state?	Source does not establish network architecture
Total HA concentration	How many mg/mL are reported, and what does the document count as total HA?	Equal concentration does not mean equal stiffness, swelling, cohesivity, or duration
Crosslinker	Is BDDE or another crosslinker identified?	A shared crosslinker does not mean a shared process or degree of modification
Manufacturing or gel technology	Which steps or structural claims are actually disclosed?	A branded technology name is not an independent clinical endpoint
Soluble or uncross-linked HA	Is an added fraction documented, and for what stated purpose?	It should not be inferred from extrusion feel or marketing language
Lidocaine and excipients	Are they included, at what concentration, and in which variant?	A suffix or family name may not transfer across markets
Presentation	What syringe volume, supplied needle or cannula, storage, and single-use instruction apply?	A similar-looking syringe is not evidence of an identical product

Crosslinking changes the finished material

Unmodified HA is naturally susceptible to turnover. Soft-tissue fillers commonly use chemical modification and crosslinking to create a more persistent gel network. The FDA notes that HA may be chemically modified through crosslinking, while exact US approval records describe the finished implant rather than approving cross-linked HA as one interchangeable formulation (FDA-approved dermal fillers 🔗).

BDDE—1,4-butanediol diglycidyl ether—is named in several product labels, but BDDE-cross-linked remains an incomplete identity. The amount and molecular weight of starting HA, reaction conditions, network processing, degree of modification, gel sizing or homogenization, purification, and addition of soluble HA can differ.

Use manufacturer technology names only as attributed product-family identifiers. They should not be silently translated into more natural, better integrated, safer, stronger, or longer lasting.

Concentration is not a performance scale

HA concentration is necessary product information, but it does not isolate the amount of cross-linked network, network structure, or in-vivo behavior. In a comparative study of 18 fillers, isolated HA concentration did not show a clear relationship with swelling factor or cohesion; relationships with G′ became more interpretable only within products sharing concentration and crosslinking technology (comparative rheologic and physicochemical study 🔗).

This means that a table containing only mg/mL can document composition but cannot support a ranking for projection, spread, tissue integration, degradation, or duration.

Two product records illustrate the limit

US product record	Documented composition	What the record establishes
Restylane Defyne	Cross-linked bacterial-source HA, 20 mg/mL; lidocaine hydrochloride, 3 mg/mL	Identity and composition of this US product record
Belotero Balance (+)	Bacterially fermented HA cross-linked with BDDE, 22.5 mg/mL; 0.3% lidocaine; prefilled syringe	Identity, composition, and presentation in this US physician label

Sources: FDA Restylane Defyne approval 🔗 and FDA Belotero Balance (+) labeling 🔗.

The different concentrations do not establish relative correction, firmness, swelling, longevity, safety, or preferred anatomy.

Monophasic and biphasic can obscure more than they explain

These labels appear frequently in filler discussions, but their definitions are not consistently applied. An experimental analysis of Juvéderm and Restylane products found observable gel particles and extractable HA in both and concluded that the common monophasic–biphasic categorization did not provide a scientifically sound selection rule (analysis of the monophasic–biphasic terminology 🔗).

Prefer descriptions tied to an actual observation or source:

• cross-linked HA network
• sized or homogenized gel, when documented
• observable gel particles under the stated method
• soluble or extractable HA fraction
• manufacturer-named technology, clearly attributed

If a source uses monophasic or biphasic, explain what that source means rather than treating the word as a universal material class.

Lidocaine and presentation belong to the exact variant

Lidocaine can be incorporated into a finished filler, and the US FDA notes that some dermal fillers contain it to reduce injection discomfort. Its presence, concentration, contraindications, and naming belong to the exact product (FDA-approved dermal fillers 🔗).

Do not infer that:

• every product in a family contains lidocaine
• a with lidocaine, L, +, or XC suffix has the same meaning across families
• a non-US product has the same formulation as a similarly named US product
• a supplied needle establishes the only clinically discussed administration tool
• syringe volume or package count can be borrowed from another market

Record the label or IFU date together with the presentation. Packaging and approved product configurations can change without creating a new headline family name.

Filler, skin booster, and hybrid are different questions

For this index, the first question is not whether a product is marketed with a familiar category word. It is:

What is the complete formulation, intended use, regulatory identity, and presentation in the market being described?

A non-cross-linked or lightly cross-linked HA injectable marketed primarily for hydration or skin-quality objectives is not automatically included as a soft-tissue filler. A comparative laboratory study was able to examine selected skin-quality boosters and fillers as defined product groups, but its product-specific results do not establish one universal material cutoff between the categories (skin-quality booster and filler comparison 🔗).

Hybrid products require the same discipline. Juvelook contains PDLLA and HA; hyaluronidase activity against an HA component would not establish removal of the whole product system.

Product identity checklist

Before comparing or linking a product, verify:

1. exact name, variant, and generation
2. market and language of the governing document
3. HA concentration and how it is reported
4. crosslinker and disclosed technology
5. soluble HA, lidocaine, and other excipients when stated
6. syringe volume, supplied tools, and storage
7. labeled indication, age, anatomy, and placement
8. developer, manufacturer, approval holder, brand owner, and distributor
9. approval or registration date and current commercial status

Then use Rheology and Physical Properties to determine whether laboratory measurements are methodologically comparable.

Do not fill missing fields by analogy

A sibling product, another market’s label, or a shared branded technology cannot supply a missing concentration, presentation, indication, placement, or physical-property value.